Multiple Myeloma

Andrzej Jakubowiak, MD, discusses the impact of a recent cross-study comparison analysis and the continued role of autologous stem cell transplantation in treatment of patients with multiple myeloma.

Maintenance lenalidomide following frontline treatment with high-dose melphalan and autologous stem cell transplant reduced the risk of death by 26% versus placebo or no maintenance in patients with multiple myeloma.

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Antonio Palumbo, MD, discusses the practice-changing findings of the phase III CASTOR trial for relapsed/refractory patients and what questions remain with the 3-drug regimen.

Michele Cavo, MD, provides insight on the results of the randomized phase III European Myeloma Network EMN02/HO95 MM trial for multiple myeloma.

The European Commission has approved carfilzomib in combination with dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.